Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Clinical Trial
Official title:
An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04632953 -
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
|
||
Terminated |
NCT04812106 -
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
|
||
Completed |
NCT03768817 -
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
|
||
Recruiting |
NCT05933200 -
A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD
|
Phase 3 |